click below
click below
Normal Size Small Size show me how
PTA Cardio Pharm
Pharmacology for Cardio Disease Management
| Term | Definition |
|---|---|
| Alpha Adrenergic Antagonist Agents | Reduce perohperal vascular tone by blocking alpha-1-adrenergic receptors; causes dilation and decrease in BP |
| ACE Inhibitor Agents | Suppresses enzyme that converts angiotensin 1 into angiotensin 2; decreasing blood pressure and after load |
| Anticoagulant Agents | Inhibit platelet aggregation and thrombus formation |
| Anti-hyperlipidemia Agents | AKA Statins; lipid modifying agents; inhibit anzyme aciton in cholesterol synthesis, break down LDL, decrease triglycerides, and increase HDL |
| Anti-thrombotic Agents | inhibit platelet aggregation and clot formation |
| Beta Blocker Agents | Block B-Adrenergic receptors; decrease myocardial oxygen demand by decreasing heart rate and contractility |
| Calcium Channel Blocker Agents | Decrease calcium entry int o calcium smooth mm cells resulting in diminished myocardial contraction, vasodilation, and oxygen demand |
| Diuretic Agents | Increase secretion of sodium and urine => reduction in plasma volume and BP; thiazide, loop and potassium sparing |
| Nitrate Agents | Decrease ischemia through smooth mm relaxation and dilation of peripheral vessels |
| Positive Inotropic Agents | Increase force and velocity of myocardial contraction; slow the heart rate; decrease conduction velocity through AV node and decrease degree of activation of SNS |
| Thrombolytic Agents | Facilitate clot dissolution through conversion of plasminogen to plasmin; plasmin breaks down clots and opens blood vessels |